Figure 1.
ASCA and anti-OmpC detection in sera and supernatants for each clinical group.
(A) Qualitative results of anti-Saccharomyces cerevisiae antibodies (ASCA) test by IFI in sera and supernatants for each clinical group. One patient is considered as ASCA positive in case of positivity of ASCA IgA and/or ASCA IgG. (B) Anti-outer membrane porine C antibodies (anti-OmpC) detection by ELISA in sera and supernatants for each clinical group.(C) Distribution of anti-OmpC antibody levels in patient sera. According to manufacturer recommendations, anti-OmpC antibody levels obtained with ELISA are considered as significant when superior or equal to 25 arbitrary units (A.U). (D) Distribution of optical densities (O.D) obtained with anti-OmpC ELISA in patient supernatants issued from culture of colonic tissues. The threshold of positivity (0.831 absorbance units) is the 97th centile of the O.D obtained for the controls + UC group. NS: no statistically significant difference. The comparison between different groups is done using the Student's t-test with p = 0.05 as significance level. CD: Crohn’s disease, UC: ulcerative colitis, Controls: patients suffering from functionnal intestinal disorders but not from CD or UC.
Table 1.
Performances of ASCA and anti-OmpC tests.
Figure 2.
Profile of ASCA and anti-OmpC antibodies in sera/supernatants of the 47 CD patients displaying at least one positive test.
ASCA: anti-Saccharomyces cerevisiae antibodies, anti-OmpC: anti-outer membrane porine C antibodies.
Table 2.
Study of IgA intestinal deposit and ASCA/anti-OmpC antibody detection in supernatants for each clinical group.
Table 3.
Study of correlation between ASCA status and CD clinical features.
Table 4.
Study of correlation between anti-OmpC antibodies status and CD clinical features.